

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY PANAMA	2. DATE OF BIRTH			2a. AGE 66 Years	3. SEX Female	3a. WEIGHT Unk	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING
		Day	Month	Year				Day	Month	Year	
		PRIVACY						Unk			

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
 Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)
Other Serious Criteria: Medically Significant
Diabetes [Diabetes]
problem she has in her brain [Brain disorder NOS]
Blood pressure pill [Blood pressure abnormal]

 Case Description: This is a spontaneous report received from a , Program ID: 164974.

 A 66-year-old female patient received axitinib (INLYTA), at 5 mg.

 (Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Inlyta (AXITINIB) Film-coated tablet		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) 5 mg	16. ROUTE(S) OF ADMINISTRATION #1) Unknown	
17. INDICATION(S) FOR USE #1) Unknown		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) Unknown	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San jose, COSTA RICA		26. REMARKS
	24b. MFR CONTROL NO. PV202500063197	
24c. DATE RECEIVED BY MANUFACTURER 22-MAY-2025	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous	
DATE OF THIS REPORT 30-MAY-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

25b. NAME AND ADDRESS OF REPORTER
 NAME AND ADDRESS WITHHELD.

30-May-2025 00:48

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: DIABETES MELLITUS (medically significant), outcome "unknown", described as "Diabetes"; CEREBRAL DISORDER (non-serious), outcome "unknown", described as "problem she has in her brain"; BLOOD PRESSURE ABNORMAL (non-serious), outcome "unknown", described as "Blood pressure pill". The action taken for axitinib was unknown. Therapeutic measures were taken as a result of diabetes mellitus, cerebral disorder, blood pressure abnormal.

Clinical course: Patient caregiver indicated; She is taking a blood pressure pill. In total, he takes three medications: one for blood pressure, one for diabetes and one prescribed for a problem he has in his brain." When asked if he uses inlyta, he does not confirm it and does not specify what he means by a brain problem. The adverse event is reported because it is not possible to confirm information.

No follow-up attempts are possible.